MeSH D048909 - diabetes complications
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D003920:Diabetes mellitus
D048909:
Diabetes complications
D003925:Diabetic angiopathies
D003926:Diabetic coma
0 Companies
0 Drugs
Success rate
D003928:Diabetic nephropathies
D003929:Diabetic neuropathies
D005320:Fetal macrosomia
0 Companies
0 Drugs
Success rate
D016883:Diabetic ketoacidosis
0 Companies
0 Drugs
Success rate
D058065:Diabetic cardiomyopathies
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Midas Pharma | Ranibizumab | Ranivisio | 2022-08-25 | |||
| Novartis | Ranibizumab | Lucentis | 2007-01-22 | $1,722 M | Q2/21-Q2/24 | |
| Stada Arzneimittel | Ranibizumab | Ximluci | 2022-11-09 |
Clinical Trials
Historical Success Rate
Phase 1
67%2/3
Phase 2
69%11/16
Phase 3
33%5/15
Approved: 4Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use